Brief: Kazia Therapeutics Provides Progress Update On Paxalisib And Evt801 Clinical Programs
30/06/2021 15:36
June 30 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* KAZIA THERAPEUTICS LTD - PROVIDES PROGRESS UPDATE ON
PAXALISIB
AND EVT801 CLINICAL PROGRAMS
* KAZIA THERAPEUTICS LTD - GBM AGILE PIVOTAL STUDY OF
PAXALISIB IS
RECRUITING AHEAD OF EXPECTATIONS, WITH ALMOST 25 SITES NOW OPEN
TO PAXALISIB ARM
* KAZIA THERAPEUTICS LTD - EVT801 PHASE I STUDY PROTOCOL HAS
BEEN
SUBMITTED TO FRENCH REGULATORY AGENCY FOR REVIEW.
Source text for Eikon: ID:nPn6wHbV8a
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt